Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
156.8 INR | +3.77% | +9.46% | +12.96% |
Sales 2024 * | 81.13B 972M 1.33B | Sales 2025 * | 92.97B 1.11B 1.53B | Capitalization | 200B 2.39B 3.28B |
---|---|---|---|---|---|
Net income 2024 * | 1.18B 14.12M 19.32M | Net income 2025 * | 5.06B 60.65M 83.02M | EV / Sales 2024 * | 2.88 x |
Net Debt 2024 * | 33.7B 404M 553M | Net Debt 2025 * | 27.93B 335M 458M | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
201
x | P/E ratio 2025 * |
39.5
x | Employees | 6,295 |
Yield 2024 * |
0.13% | Yield 2025 * |
0.33% | Free-Float | 26.56% |
Latest transcript on Piramal Pharma Limited
1 day | +3.84% | ||
1 week | +9.46% | ||
Current month | +9.19% | ||
1 month | +12.84% | ||
3 months | +11.32% | ||
6 months | +44.56% | ||
Current year | +12.96% |
Managers | Title | Age | Since |
---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 20-03-03 |
Vivek Valsaraj
PSD | President | 51 | 20-06-09 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 20-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 43 | 21-01-03 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
Director/Board Member | 76 | 21-02-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 7 M€ | +3.48% | - | |
0.00% | 117 M€ | +2.11% | - | |
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 156.8 | +3.77% | 23 739 129 |
24-05-03 | 151 | +5.37% | 26,693,210 |
24-05-02 | 143.4 | -0.21% | 1,306,760 |
24-04-30 | 143.6 | +0.24% | 3,126,412 |
24-04-29 | 143.3 | +0.74% | 3,241,028 |
Delayed Quote NSE India S.E., May 06, 2024 at 04:57 am
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.96% | 2.4B | |
+26.08% | 662B | |
+22.35% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.23% | 198B | |
-11.04% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- PPLPHARMA Stock